Tyrosine kinase inhibitor (TKI)

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Emory University, Pfizer

Conditions

Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRenal Cell Carcinoma (RCC)

Phase 1

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

CompletedNCT01460498

M.D. Anderson Cancer CenterLeukemia

Start: 2012-08-08End: 2019-08-07Updated: 2020-03-05

Phase 2

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

TerminatedNCT02730195

Emory UniversityChronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Start: 2016-05-31End: 2018-07-31Updated: 2019-01-09

Unknown Phase

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

CompletedNCT04375150

PfizerRenal Cell Carcinoma (RCC)

Start: 2019-12-02End: 2022-10-28Updated: 2024-09-19